Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EnterVR
Jerusalem, Israelentervr.no ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
EnteraBio develops oral tablet formulations of peptides and proteins for diseases with high unmet need. Its lead program EB613, an oral parathyroid hormone fragment for osteoporosis, has shown positive results in a Phase 2 trial demonstrating early impact on bone compartments after six months of treatment in postmenopausal women with osteoporosis. Other programs are at preclinical or early clinical stages.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- PeptidesProteinSmall molecule (for absorption enhancers)Biologic (for peptide/protein drugs)
- Industry
- Biotech
02
Partnerships
OPKO Health (collaboration on oral GLP‑2 for short bowel syndrome)
Beyond the preview
Go deeper on EnterVR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnterVR.